Covid-19
Shionogi starts Phase I trial of Covid-19 antiviral in Japan
The trial will assess the pharmacokinetics, safety, and tolerability of S-892216 in healthy adults.
The trial will assess the pharmacokinetics, safety, and tolerability of S-892216 in healthy adults.